Biotech and Pharmaceuticals Pharmaceuticals

More

  • FDA scientists early on Friday released their supportive findings ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. South Korea's Celltrion and partner Pfizer Inc want to sell Remsima in the United States as a cut-price copy of Johnson& Johnson and Merck& Co's Remicade, or infliximab, which had global 2014 sales of...

  • Feb 4- U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency. FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an...

  • Robert Califf, President Barack Obama's nominee to lead the Food and Drug Administration, said on Thursday the agency would reform its process for approving opioid painkillers. The FDA said it has agreed to convene a committee before approving any new opioid that does not have abuse-deterrent properties. Califf, who joined the FDA a year ago as a deputy...

  • Merrimack CEO: Face of pharma isn't a bad actor Thursday, 4 Feb 2016 | 2:14 PM ET
    Merrimack CEO: Face of pharma isn't a bad actor

    Merrimack Pharmaceuticals develops products to treat cancer. President and CEO Bob Mulroy, shares his view of drug price hikes and whether the FDA is in the way of companies.

  • Chaffetz: 'Sort of childlike' behavior from Shkreli Thursday, 4 Feb 2016 | 1:55 PM ET
    Chaffetz: 'Sort of childlike' behavior from Shkreli

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, comments on former Turing Pharmaceuticals CEO Martin Shkreli's tweet calling the Congressional committee "imbeciles."

  • Chaffetz: Believe in profit, but I take issue with misrepresenting drugs

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, reflects on former Turing Pharmaceuticals CEO Martin Shkreli's behavior on Capitol Hill, and the debate on drug prices and the role of government.

  • Martin Shkreli takes on Congress Thursday, 4 Feb 2016 | 12:12 PM ET
    Martin Shkreli, former CEO of Turing Pharmaceuticals, prepares to testify before a House Oversight and Government Reform hearing on Capitol Hill, Feb. 4, 2016.

    Martin Shkreli, the former drug company CEO who's come under fire for massive drug price increases, refused to testify Thursday before a congressional committee investigating drug price hikes.

  • Martin Shkreli on the Hill Thursday, 4 Feb 2016 | 9:20 AM ET
    Martin Shkreli on the Hill

    House Oversight Chairman Jason Chaffetz swears in the panel at the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli is testifying.

  • Jim Cramer: Drug price hearing 'not for show' Thursday, 4 Feb 2016 | 9:06 AM ET
    Jim Cramer: Drug price hearing 'not for show'

    The "Squawk on the Street" crew discuss the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli, and Valeant Pharmaceuticals interim CEO Howard Schiller are testifying.

  • AstraZeneca CEO open for deals that pay from day one Thursday, 4 Feb 2016 | 8:25 AM ET

    LONDON, Feb 4- After a three-year rebuild, Chief Executive Pascal Soriot reckons AstraZeneca's drug pipeline is now "full", but he's still hungry for acquisitions that pay for themselves straight away. Late last year, the British-based drugmaker made two acquisitions that will dilute in earnings in the short term, paying $2.7 billion for ZS Pharma and $4 billion...

  • Martin Shkreli testifies on Capitol Hill Thursday, 4 Feb 2016 | 7:53 AM ET
    Martin Shkreli testifies on Capitol Hill

    Former Turing Pharmaceuticals executive Martin Shkreli will appear before Congress this morning, reports CNBC's Meg Tirrell.

  • *Q4 core EPS 94 cents vs consensus 95 cents. *Q4 revenue $6.40 billion vs consensus $6.29 billion. LONDON, Feb 4- AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling cholesterol drug, which will offset growth in sales of newer medicines.

  • AstraZeneca warns on 2016 as it fights generic drugs Thursday, 4 Feb 2016 | 2:17 AM ET

    Pharma group expects a decline in earnings in 2016 as the arrival of cheap generic copies of cholesterol fighter Crestor offsets growth.

  • Florida governor declares Zika emergency Wednesday, 3 Feb 2016 | 3:44 PM ET
    Aedes aegypti mosquitos known to carry the Zika virus.

    Florida Governor Rick Scott has declared a health emergency in four counties due to the Zika virus.

  • Shkreli attorney: I told him to stop talking Wednesday, 3 Feb 2016 | 3:35 PM ET
    Former drug executive Martin Shkreli (R) exits with his lawyer Benjamin Brafman at the U.S. Federal Courthouse in Brooklyn, New York February 3, 2016.

    After his hearing at Brooklyn court on Wednesday, Martin Shkreli will no longer be speaking to the press according to his new lawyer.

  • NEW YORK, Feb 3- Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud. The $3 million settlement equals 7 percent to 10 percent of the $26 million to $41...

  • New lawyer silences bad-boy ex-pharma CEO Martin Shkreli Wednesday, 3 Feb 2016 | 11:32 AM ET

    NEW YORK— Bad-boy ex-pharmaceutical company CEO and prolific social media user Martin Shkreli has been muzzled. "We want to try this case in the courtroom and not in the media," defense attorney Benjamin Brafman said with a silent Shkreli at his side following a pretrial hearing in Brooklyn. Shkreli, 32, gained notoriety last year after a drug company he founded,...

  • LONDON, Feb 3- GlaxoSmithKline said on Wednesday the chance of it spinning off or selling its consumer health business before 2018 was "extraordinarily low," arguing the group's strategy was delivering, helped by rising sales of new medicines. Growing demand for recently launched HIV and respiratory drugs helped Britain's biggest drugmaker beat forecasts...

  • NEW YORK, Feb 3- Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose various transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud. The $3 million settlement equals 7 percent to 10 percent of the $26 million...

  • NEW YORK, Feb 3- Retrophin Inc has agreed to pay $3 million to resolve a lawsuit by investors accusing the pharmaceutical company of failing to disclose various transactions that benefited former Chief Executive Officer Martin Shkreli, who has since been indicted for securities fraud. The $3 million settlement equals 7 percent to 10 percent of the $26 million...